Company intelligence / Profile preview

AuriGen Medical

Ownership: Private
Development stage: Phase 1

Overview

AuriGen Medical has successfully completed a first-in-human procedure with its Zenith left atrial appendage occlusion (LAAO) device. The Zenith device is designed to both electrically and physically isolate the LAA, aiming to reduce stroke and arrhythmia risk in patients with longstanding persistent atrial fibrillation. Initial clinical results indicate successful implantation and positive patient recovery, representing a significant advance over existing LAAO technologies.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically, cardiac implant/occluder)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Zenith

Phase 1

Indications: Atrial fibrillation, Stroke prevention

Partnerships

Horizon 2020 SME Instrument & Fast Track to Innovation programs

Beyond the preview

Go deeper on AuriGen Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AuriGen Medical.

Explore the full profile